Surf Bio is a preclinical biopharmaceutical company that is leveraging a novel biotechnology platform to develop enhanced therapeutic solutions for oncology, autoimmune diseases, infectious diseases, gene therapy, and other therapeutic areas. Surf Bio was launched by the founders of Bigfoot Biomedical and Mode AGC to commercialize a breakthrough drug stabilization technology developed in the Appel lab at Stanford University. Commercially, the technology is designed to enable reduction of refrigeration requirements, transition from IV to subcutaneous therapy, and novel pharmaceutical formulations across a range of therapeutic areas.